Literature DB >> 9623398

Influence of five years of antenatal screening on the paediatric cystic fibrosis population in one region.

S Cunningham1, T Marshall.   

Abstract

BACKGROUND: Antenatal screening for cystic fibrosis has been endorsed by the US National Institutes of Health. Edinburgh is the only city in the UK with an established routine antenatal screening programme for cystic fibrosis. AIMS: To report the change in numbers of infants diagnosed with cystic fibrosis born in Edinburgh after the introduction of antenatal screening for the disease. POPULATION: Infants diagnosed as having cystic fibrosis (by sweat test or genotyping, or both) in the seven years before antenatal testing (1984-90) and the first five years of antenatal testing (1991-95). Children born in this region who had moved before diagnosis were identified from the UK cystic fibrosis survey database.
RESULTS: The incidence of cystic fibrosis decreased from an average of 4.6 to 1.6 children each year with antenatal screening. The reduction in the incidence (65%) was greater than that accounted for by prenatal diagnosis and termination (36%). Of the eight children born with cystic fibrosis during the period of antenatal screening, five had been subject to antenatal screening: three had only one mutation identified, one was missed due to a laboratory error, and one was identified as a one in four risk, but prenatal diagnosis was not performed.
CONCLUSIONS: Antenatal testing for cystic fibrosis has successfully reduced the incidence of cystic fibrosis in this region. Although the numbers are small, it is possible that the reduction in numbers may have been greater than might be expected from antenatal screening alone.

Entities:  

Mesh:

Year:  1998        PMID: 9623398      PMCID: PMC1717529          DOI: 10.1136/adc.78.4.345

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-Up Study Group.

Authors:  D Axworthy; D J Brock; M Bobrow; T M Marteau
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

2.  US endorses testing for cystic fibrosis in pregnant women.

Authors:  N Macready
Journal:  BMJ       Date:  1997-05-03

3.  Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening.

Authors:  J E Dankert-Roelse; G J te Meerman; A Martijn; L P ten Kate; K Knol
Journal:  J Pediatr       Date:  1989-03       Impact factor: 4.406

4.  Effect of screening for cystic fibrosis on the influence of genetic counseling.

Authors:  J E Dankert-Roelse; G J te Meerman; K Knol; L P ten Kate
Journal:  Clin Genet       Date:  1987-10       Impact factor: 4.438

5.  Neonatal screening for cystic fibrosis.

Authors:  P D Phelan
Journal:  Thorax       Date:  1995-07       Impact factor: 9.139

6.  Prenatal screening for cystic fibrosis: 5 years' experience reviewed.

Authors:  D J Brock
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

7.  Cost effectiveness of antenatal screening for cystic fibrosis.

Authors:  H S Cuckle; G A Richardson; T A Sheldon; P Quirke
Journal:  BMJ       Date:  1995-12-02

8.  Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis.

Authors:  L N al-Jader; M C Goodchild; H C Ryley; P S Harper
Journal:  Clin Genet       Date:  1990-12       Impact factor: 4.438

Review 9.  Delayed diagnosis of cystic fibrosis in children with a rare genotype (delta F508/R117H).

Authors:  D Fitzgerald; P Van Asperen; R Henry; D Waters; M Freelander; M Wilson; B Wilcken; K Gaskin
Journal:  J Paediatr Child Health       Date:  1995-06       Impact factor: 1.954

10.  Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening.

Authors:  S Chatfield; G Owen; H C Ryley; J Williams; M Alfaham; M C Goodchild; P Weller
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

View more
  10 in total

1.  Shock, adjust, decide: reproductive decision making in cystic fibrosis (CF) carrier couples--a qualitative study.

Authors:  Jessica Myring; William Beckett; Rupinder Jassi; Theresa Roberts; Richard Sayers; Diana Scotcher; Marion McAllister
Journal:  J Genet Couns       Date:  2011-04-05       Impact factor: 2.537

2.  Reproductive decisions after neonatal screening identifies cystic fibrosis.

Authors:  T Dudding; B Wilcken; B Burgess; J Hambly; G Turner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

3.  The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era.

Authors:  Avantika Mishra; Ronda Greaves; John Massie
Journal:  Clin Biochem Rev       Date:  2005-11

Review 4.  Cystic fibrosis during pregnancy.

Authors:  Alexander Liaschko; Gideon Koren
Journal:  Can Fam Physician       Date:  2002-03       Impact factor: 3.275

Review 5.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 6.  Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application.

Authors:  Kateryna Kratzer; Landon J Getz; Thibaut Peterlini; Jean-Yves Masson; Graham Dellaire
Journal:  Hum Genet       Date:  2021-04-08       Impact factor: 4.132

Review 7.  Prioritising the application of genomic medicine.

Authors:  Brett Doble; Deborah J Schofield; Tony Roscioli; John S Mattick
Journal:  NPJ Genom Med       Date:  2017-11-21       Impact factor: 8.617

8.  Clinical Utility of Expanded Carrier Screening: Reproductive Behaviors of At-Risk Couples.

Authors:  Caroline E Ghiossi; James D Goldberg; Imran S Haque; Gabriel A Lazarin; Kenny K Wong
Journal:  J Genet Couns       Date:  2017-09-27       Impact factor: 2.537

9.  Cystic fibrosis carrier screening effects on birth prevalence and newborn screening.

Authors:  Carlo Castellani; Luigi Picci; Gloria Tridello; Elia Casati; Anna Tamanini; Lucia Bartoloni; Maurizio Scarpa; Baroukh M Assael
Journal:  Genet Med       Date:  2015-06-18       Impact factor: 8.822

10.  Some ethical issues in the prenatal diagnosis of sickle cell anaemia.

Authors:  Joseph O Fadare
Journal:  Ann Ib Postgrad Med       Date:  2009-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.